Program
senicapoc
Also written as “ICA-17043”, “Senicapoc” and “Low Dose ICA-17043”.
Its studies are mostly in Anemia, Sickle Cell · Asthma, Exercise-Induced · Asthma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Icagen | 50 open or running | phase 3since Feb 1, 2005 | Jul 8, 2002 | none ahead |
| Biossil | 11 open or running | phase 2since Nov 13, 2025 | Nov 13, 2025 | Oct 2029phase 2 · NCT07282210 |
Also a collaborator on its studies: Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2002First study: phase 2 study in Anemia, Sickle CellNew to IcagenIcagen · NCT00040677 · 90 enrolled · United States
- Feb 1, 2005Phase 3 study in Anemia, Sickle CellIcagen · NCT00102791 · 297 enrolled · United States, Brazil, France and more
- Feb 21, 2006Phase 3 study in Anemia, Sickle CellIcagen · NCT00294541 · 51 enrolled · United States
- Mar 12, 20092 phase 2 studiesIcagen · NCT00861211, NCT00861185
- Nov 13, 2025Biossil's first study: phase 2 study in Anemia, Sickle CellNew to BiossilBiossil · NCT07282210 · 65 planned · Canada
Ahead
- Oct 2029Primary completion: phase 2 study in Anemia, Sickle CellBiossil · NCT07282210
TargetBeta
“An orally bioavailable inhibitor of the calcium-activated potassium channel KCa3.1 (Gardos channel; KCNN4; IK-1; SK4), ”NCIt, by rule
“Intermediate conductance calcium-activated potassium channel protein 4 blocker”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07282210Anemia, Sickle Cell · Canada | 2 | Recruiting | Biossil | Oct 2029 | 65 |
| NCT00861211Asthma · United Kingdom | 2 | Completed | Icagen | Mar 2009 | 34 |
| NCT00861185Asthma, Exercise-Induced · United States | 2 | Completed | Icagen | Jul 2009 | 69 |
| NCT00294541Anemia, Sickle Cell · United States | 3 | Terminated | Icagen | 51 | |
| NCT00102791Anemia, Sickle Cell · United States, Brazil, France and more | 3 | Terminated | Icagen | 297 | |
| NCT00040677Anemia, Sickle Cell · United States | 2 | Completed | Icagen | Nov 2003 | 90 |
How it is read
Names in the registry
- “senicapoc”, 2 entries
- “ICA-17043”, 2 entries
- “Senicapoc”, 1 entry
- “Low Dose ICA-17043”, 1 entry
- “High dose ICA-17043”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 4 studies
- Asthma, Exercise-Induced, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.